Payment overview · 2025
General Payments
$897.20
49 reported records · 19 companies
Healthcare provider profile · identity verified
Bryan Thomas Kirkland, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MONROE, GA · NPI 1821018441
Verified facts
What the public records show
CMS Open Payments records show Bryan Thomas Kirkland, MD received $897.20 in general payments during 2025 across 49 reported records.
Novo Nordisk Inc accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.02 | 18.2% | 12 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $101.38 | 11.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $100.95 | 11.2% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $70.09 | 7.8% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $62.95 | 7.0% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $54.61 | 6.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.91 | 5.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.95 | 5.3% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $30.51 | 3.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.96 | 3.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.21 | 3.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.65 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.07 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.82 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.56 | 2.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.05 | 2.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.26 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.71 | 1.6% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $14.54 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $897.20 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $148.00 | 10 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $101.38 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $70.09 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $62.95 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $54.61 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $48.91 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $30.51 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.96 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.96 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $28.96 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.26 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.02 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.02 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 471 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 98 |
| Losartan Potassium | Losartan Potassium | 367 | 105 |
| Gabapentin | Gabapentin | 335 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 77 |
| Montelukast Sodium | Montelukast Sodium | 276 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 62 |
| Trazodone Hcl | Trazodone Hcl | 261 | 71 |
| Lisinopril | Lisinopril | 259 | 88 |
| Metformin Hcl | Metformin Hcl | 238 | 74 |
| Furosemide | Furosemide | 237 | 62 |
| Omeprazole | Omeprazole | 197 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 174 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 171 | 68 |
| Tramadol Hcl | Tramadol Hcl | 152 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 52 |
| Famotidine | Famotidine | 137 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 127 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 52 |
| Potassium Chloride | Potassium Chloride | 121 | 31 |
| Donepezil Hcl | Donepezil Hcl | 118 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 33 |
| Meloxicam | Meloxicam | 109 | 31 |
| Ozempic | Semaglutide | 109 | 26 |
| Carvedilol | Carvedilol | 108 | 33 |
| Eliquis | Apixaban | 100 | 26 |
| Sertraline Hcl | Sertraline Hcl | 100 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 32 |
| Bupropion Xl | Bupropion Hcl | 89 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 30 |
| Xarelto | Rivaroxaban | 76 | 14 |
| Allopurinol | Allopurinol | 74 | 18 |
| Alprazolam | Alprazolam | 72 | 15 |
| Januvia | Sitagliptin Phosphate | 71 | 15 |
| Prednisone | Prednisone | 69 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 18 |
| Mounjaro | Tirzepatide | 68 | 14 |
| Simvastatin | Simvastatin | 67 | 21 |
| Metformin Hcl Er | Metformin Hcl | 65 | 25 |
| Ezetimibe | Ezetimibe | 63 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 14 |
| Pregabalin | Pregabalin | 61 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 17 |
| Finasteride | Finasteride | 57 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 47 |
| Glipizide | Glipizide | 56 | 19 |
| Alendronate Sodium | Alendronate Sodium | 55 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 28 |
| Buspirone Hcl | Buspirone Hcl | 51 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 11 |
| Jardiance | Empagliflozin | 50 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 11 |
| Glimepiride | Glimepiride | 46 | 13 |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Rybelsus | Semaglutide | 46 | 14 |
| Memantine Hcl | Memantine Hcl | 44 | 11 |
| Spironolactone | Spironolactone | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 23 |
| Atenolol | Atenolol | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | 11 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | 11 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Valsartan | Valsartan | 33 | 12 |
| Myrbetriq | Mirabegron | 30 | 11 |
| Primidone | Primidone | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | 11 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 23 |
| Ondansetron Odt | Ondansetron | 28 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | 11 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 11 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | 11 |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 11 |
| Nystatin | Nystatin | 21 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Trulance | Plecanatide | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $897.20 · 49 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, KRYSTEXXA, Korlym, LINZESS, Leqembi, MOUNJARO, NEFFY, NP Thyroid 60, NURTEC ODT, Ozempic, PREVNAR 20, ROTATEQ, Rybelsus, The Cologuard Plus Collection Kit, Tymlos, VAXNEUVANCE, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error